Damora Therapeutics (DMRA) Assets Average (2020 - 2026)

Damora Therapeutics has reported Assets Average for 7 years, with the latest figure at $398.0 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 2349.36% year-over-year to $398.0 million; the trailing twelve-month figure through Mar 2026 stood at $398.0 million (up 2349.36% YoY), and the FY2025 full-year result was $138.8 million, up 401.56% from the prior year.
• Assets Average for Q1 2026 stood at $398.0 million, up from $135.6 million in the prior quarter.
• The five-year high for Assets Average was $398.0 million in Q1 2026, with the low at $12.2 million in Q3 2025.
• Historically, Assets Average has averaged $76.4 million across 5 years, with a median of $54.4 million in 2023.
• Annual changes were most pronounced in 2024 — Assets Average plunged 54.11% — and 2026, when it jumped 2349.36%.
• Damora Therapeutics' Assets Average stood at $77.6 million in 2022, then sank by 43.13% to $44.1 million in 2023, then plunged by 54.11% to $20.3 million in 2024, then surged by 569.65% to $135.6 million in 2025, then surged by 193.43% to $398.0 million in 2026.
• The last three Assets Average figures came in at $398.0 million (Q1 2026), $135.6 million (Q4 2025), and $12.2 million (Q3 2025), per Business Quant data.